FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS).
“Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,” said Dr Lakshmi Kotra, CEO of Lucid Psycheceuticals. “The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.”
The clinical trial is a randomised, double-blind, placebo controlled, single ascending dose and multiple ascending dose study with the primary outcomes evaluating the safety, tolerability, and pharmacokinetics of Lucid-MS in healthy volunteers under fed and fasted conditions.
Lucid-MS is a patented first-in-class, new chemical entity and a neuroprotective compound with a novel mechanism of action for the treatment of MS.
In preclinical models, Lucid-MS has been shown to prevent myelin degradation (demyelination), a hallmark pathology feature of MS and other neurogenerative diseases characterised by damage to the myelin sheath surrounding nerve fibres in the central nervous system.
Preclinical evidence has demonstrated Lucid-MS to promote functional recovery in experimental animal models of MS. Based on current evidence, Lucid-MS is non-immunomodulatory agent, an important distinction in the potential for developing new, safe options for treating MS.
